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Abstract: In obesity, dysregulated metabolism and aberrant expansion of adipose tissue lead 
to the development of tissue hypoxia that plays an important role in contributing to obesity-
  associated metabolic disorders. Recent studies utilizing adipocyte-specific hypoxia-inducible 
factor-α (HIF-α) gain- or loss-of-function animal models highlight the pivotal involvement of 
hypoxic responses in the pathogenesis of obesity-associated inflammation and insulin resistance. 
HIF-1α, a master transcription factor of oxygen homeostasis, induces inflammation and insulin 
resistance in obesity, whereas its isoform, HIF-2α, exerts opposing functions in these obesity-
associated metabolic phenotypes. In this review, recent evidence elucidating functional implica-
tions of adipocyte HIFs in obesity and, more importantly, how these regulate obesity-associated 
inflammation, fibrosis, and insulin resistance will be discussed. Further, we propose that modula-
tion of HIF-1 could be a potential novel therapeutic strategy for antidiabetic treatment.
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Introduction
Hypoxia has been the focus of intensive investigation mainly due to its functional and 
clinical implication in numerous pathological conditions including cancer, inflamma-
tion, tissue injury, and ischemic diseases.1 It has been known for many decades that 
hypoxia is one of the prominent factors that influence energy balance and obesity 
from initial metabolic studies among high-altitude population and obstructive sleep 
apnea patients.2 Intriguingly, there is a significant inverse relationship between body 
mass index and altitude of residence, whereas obstructive sleep apnea patients display 
oxidative stress, systemic hypertension, and hypoxia-inducible factor (HIF) dependent 
inflammation. Although these seemingly contradictory effects of hypoxia highlight the 
important and complicated role of hypoxia on energy balance and metabolism, little 
is known about key molecules and signaling pathways in the relationship between 
hypoxia and obesity.
Hypoxia occurs when oxygen demand exceeds supply, which results in insufficient 
oxygen supply into tissues or cells. Recent animal studies have demonstrated that 
adipose tissues become hypoxic in obesity.3–5 Potential contributors to the onset of 
adipose tissue hypoxia in obesity include: 1) inadequate blood flow to white adipose 
tissues;6 2) overall increase in adipocyte size, which is larger than oxygen’s diffu-
sion capacity of 150–200 µm;7 or 3) enhanced oxygen consumption by adipocytes 
or inflammatory cells infiltrated into the obese microenvironment.8–10 Yet, molecular 
and cellular mechanisms that initiate and maintain the hypoxic microenvironment in 
obese adipose tissues remain to be elucidated.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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Glucose intolerance is characterized by systemic 
hyperglycemia due to impaired glucose absorption and 
utilization by cells, and is considered as a prediabetic state 
associated with insulin resistance.11 About 80%–90% of 
people diagnosed with type 2 diabetes are also diagnosed 
as obese.12 A number of preclinical and clinical studies have 
suggested that chronic inflammation may be the crucial link 
between obesity and insulin resistance.13–15 Virtually all obese 
animals and humans display low-grade chronic inflammation 
in their adipose tissues, which is characterized by proinflam-
matory macrophage infiltration and oxidative stress. Given 
that hypoxia is one of the prominent regulators for inflamma-
tion and reactive oxygen species production,16–19 hypoxia and 
cellular hypoxic responses may provide mechanistic insight 
into causal relationships between obesity, inflammation, and 
insulin resistance.20
HIFs, oxygen-sensitive transcriptional regulators, 
mediate cellular and microenvironmental hypoxic remod-
eling.21 Upon oxygen deprivation, alpha subunits of HIFs 
are stabilized, translocated to the nucleus, and bound to 
hypoxia responsive elements to induce hypoxia-regulated 
gene expression. Recently, we and other groups, utilizing 
animal model systems, reported that adipocyte-specific 
constitutively active HIF-1α expression aggravates diabetic 
phenotypes with adipose tissue inflammation and fibrosis. 
Furthermore, loss of HIF-1α in adipocytes significantly 
attenuates obesity-associated inflammation and improves 
insulin sensitivity.22–26 These findings argue for critical 
involvement of hypoxic HIF-1 signaling in metabolic dis-
orders in obese mice. However, little is known about how 
the hypoxic adipose microenvironment affects the biology 
of adipocytes and other critical cell components in obesity 
such as macrophages. Moreover, recent studies by our group 
and others utilizing animal models with cell type-specific 
knocking-out or overexpression of genes in hypoxic sig-
naling pathways demonstrated that different types of cells 
differentially respond to hypoxia, and further, exhibit unique 
hypoxic responses and phenotypes.27–35 This suggests that 
there may be multidirectional interaction among adipocytes 
and surrounding non-adipocytes including macrophages, 
endothelial cells, and various mesenchymal cells. Addi-
tionally, it should be noted that independently established 
aP2-cre mice display differential temporal/spatial Cre 
expression in adipocytes as well as in non-adipocytic 
lineage cells including myeloid and neuronal cells.36 This 
may be responsible for seemingly contradictory phenotypes 
among the various HIFs gain- and loss-of-function mouse 
models (Table 1).
In this review, we will describe the functional effects of 
HIF signaling on metabolically dysfunctional adipocytes and 
how this modulates obesity and insulin resistance. Although 
non-adipose tissue HIF signaling has been implicated in 
obesity and other metabolic disorders, this has been elegantly 
reviewed elsewhere37 and will not be discussed here. We will 
also discuss inhibition of HIF signaling as a potential thera-
peutic target for obesity and metabolic diseases.
HIFs
The HIF proteins are central transcription factors of oxygen 
homeostasis. HIFs are a heterodimeric complex composed of 
an α and a β subunit. Both the subunits belong to the basic 
helix-loop-helix Per/Arnt/Sim (PAS) family of transcrip-
tion factors and are constitutively expressed in the cell. The 
HIF-α subunit is oxygen-sensitive and is rapidly degraded 
in nonhypoxic conditions with a half-life of less than 
10 minutes,38 whereas the HIF-β subunit is constitutively 
expressed.39 In the presence of ample oxygen, the prolyl and 
asparaginyl hydroxylases hydroxylate the oxygen-dependent 
domain (ODD) of HIF-α on specific proline and asparag-
ine residues, respectively.40–42 Prolyl hydroxylases (PHDs) 
require molecular oxygen, Fe(II), ascorbate, and the Krebs 
cycle intermediate, 2-oxoglutarate, as substrates.40,41 Proline 
hydroxylation allows the von Hippel–Lindau protein, a tumor 
suppressor E3 ubiquitin ligase, to bind and target HIF-α for 
proteasome degradation via polyubiquitination, whereas 
asparaginyl hydroxylation inhibits transcription activities 
of HIFs by blocking HIF interaction with the transcriptional 
cofactor, p300.42–45 In response to hypoxic conditions, the 
lack of available molecular oxygen, an absolute requirement 
for HIF hydroxylation, stabilizes HIF-α increasing cellular 
levels of the protein and facilitating its translocation into 
the nucleus. In the nucleus, HIF-α heterodimerizes with 
HIF-β and forms complexes with other coactivators, such 
as p300, in order to bind to hypoxia-responsive elements of 
genomic DNA and to transactivate its target genes (Figure 1). 
In addition to oxygen availability, inducible changes in 
the cellular abundance of the PHDs (PHD1–3) provide an 
additional interface that regulates the oxygen-sensitive HIF 
signaling.46
There are three HIF-α subunits identified: HIF-1α, -2α, 
and -3α. HIF-1α has been most-extensively   characterized. 
HIF-1α mediates adaptation and survival to hypoxia 
through activating genes involved in angiogenesis (eg, vas-
cular endothelial growth factor [VEGF]), glucose uptake 
(eg, glucose transporter 1), and glycolysis (eg, lactate 
dehydrogenase and pyruvate dehydrogenase kinase 1).47 Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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Although another isoform, HIF-2α, also termed endothelial 
PAS domain-containing protein 1, shares similar functional 
homology and common target genes to HIF-1α,48 recent 
studies have demonstrated that they have non-overlapping 
target genes that are uniquely involved in HIF-2α-mediated 
cellular processes such as erythropoietin and the stem cell 
factor octamer-binding transcription factor 4.49–52 Fur-
thermore, HIF-1α and HIF-2α appear to have opposing 
activities in certain contexts.53 In von Hippel–Lindau tumor 
suppressor (VHL)-null renal cell carcinoma cells, where 
both HIF-1α and HIF-2α are constitutively active, HIF-2α 
may function as a tumor-  promoting player whereas HIF-1α 
exhibits tumor-suppressing activities.54,55 This counteraction 
of the two isoforms may be mediated in part by functional 
crosstalk between HIF-αs and the proto-oncogene c-Myc.56 
When HIF-1α is available, it attenuates c-Myc transcriptional 
activity by disrupting c-Myc/Max complexes. On the other 
hand, HIF-2α associates with Max, stabilizing the c-Myc/
Max complexes and enhancing c-Myc transcriptional activ-
ity. More opposing functions of HIF-1α and HIF-2α have 
been shown to be critical in nitric oxide (NO) homeostasis 
of macrophages, keratinocytes, and endothelial cells.28,33,57 
HIF-1α induces the expression of inducible nitric oxide 
synthase (iNOS), which increases the production of NO. 
HIF-2α, on the other hand, induces arginase expression, 
which inhibits NO production by removing L-arginine, a 
substrate for NO   production.   Consistent with these previ-
ous findings, our recent study suggested that these opposing 
functions of HIF-1α and HIF-2α are critically involved in 
the pathogenesis of adipocyte dysfunction in obesity.58 We 
will discuss in more detail the functional effects of HIFs on 
obesity and insulin resistance in this review.
Adipose tissue hypoxia in obesity
While atmosphere oxygen tension is 160 mmHg (21%), 
physiological oxygen levels vary significantly between 
the tissues from 150 mmHg (17%) in the upper respira-
tory tract to 1–10 mmHg in the retina.20 Although human 
clinical studies have reported contradictory results in the 
levels of adipose tissue blood flow and oxygenation in 
obese subjects,59–62 direct measurement of oxygen tension 
by   oxygen-meters revealed that oxygen tension in white 
adipose tissue in obese mice (leptin-deficient mutant ob/ob 
mice) and high-fat fed mice is approximately 15 mmHg 
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Figure 1 Oxygen-dependent regulation of HiF-1α.
Notes: when ample oxygen is present, proline residues in the ODD of the HiF-1α subunit are hydroxylated by PHDs that require oxygen as a substrate. The hydroxylated 
HiF-1α subunit is then recognized and bound by vHL, which targets HiF-1α for polyubiquitination and proteasomal degradation. HiF-1α asparagine residue is hydroxylated 
by the FiH blocking HiF-1α association with coactivator p300, which in turn prevents full transcriptional activation of HiF-1. Under hypoxic conditions, enzymatic activity of 
PHDs and FiH is inhibited and HiF-1α subunits are stabilized and translocated to the nucleus, where with binding partner HiF-1β and coactivator p300, HiF-1 binds to the 
HRes in the promoter of target genes that are involved in the process of hypoxic adaptation and survival.
Abbreviations: BNiP3, BCL2/adenovirus e1B 19kDa protein-interacting protein 3; CA iX, carbonic anhydrase iX; ePO, erythropoietin; FiH, factor-inhibiting HiF; Glut, 
glucose transporter; HiF, hypoxia-inducible factor; HK, hexokinase; HRes, hypoxia-response elements; LDHA, lactate dehydrogenase A; ODD, oxygen-dependent domain; 
PHDs, prolyl hydroxylases; SCF, Skp1–Cul1–F-box-protein; veGF, vascular endothelial growth factor; Ub, ubiquitin; vHL, von Hippel–Lindau tumor suppressor protein.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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Table 1 in vivo and in vitro models for adipocyte HiFs
Cre/promoter Expression (nonadipose) HFD Metabolic phenotypes
In vivo studies
HIF-1α gain-of-function 
Halberg et al22
 
aP2-HiF-1α- 
ODDΔ
 
wAT, BAT 
(macrophage22)
 
12 wks
 
Body weight and AT mass 
Glucose intolerance  
AT Inflammation and fibrosis 
HIF-1α loss-of-function 
Jiang et al23 
 
 
Kihira et al24 
 
 
 
Lee et al58 
 
 
Krishnan et al25 
 
 
Zhang et al78
 
aP2-Cre* 
 
 
aP2-Cre** 
 
 
 
aP2-Cre** 
 
 
aP2-Cre-eRT 
 
 
aP2-DN-HiF-1α
 
wAT, BAT, (CNS, PNS, heart,  
muscle, testis, macrophage36,107)  
 
wAT, BAT (CNS, PNS36,108,109) 
 
 
 
wAT, BAT,(CNS, PNS36,108,109) 
 
 
wAT, BAT, (heart, muscle,  
salivary gland36) 
 
Not determined
 
12 wks 
 
 
15 wks 
 
 
 
15 wks 
 
 
27 wks 
 
 
28 wks
 
Body weight and AT mass  
Glucose intolerance and insulin resistance  
AT Inflammation and fibrosis  
Body weight and AT mass  
Glucose intolerance and insulin resistance  
AT Inflammation  
 
AT mass  
Glucose intolerance and insulin resistance  
AT inflammation and fibrosis  
Body weight and AT mass  
Glucose intolerance and insulin resistance  
Cardiomyopathy  
Body weight and AT mass  
Glucose intolerance and insulin resistance  
AT inflammation 
HIF-1β loss-of-function 
Jiang et al23 
 
 
Lee et al26
 
aP2-Cre* 
 
 
aP2-Cre*
 
wAT, BAT, (CNS, PNS, heart,  
muscle, testis, macrophage36,107)  
 
wAT, BAT, (CNS, PNS, heart,  
muscle,  testis, macrophage36,107)
 
12 wks 
 
 
12 wks
 
Body weight and AT mass  
Glucose intolerance and insulin resistance  
AT inflammation  
Body weight and AT mass  
Glucose intolerance and insulin resistance 
HIF-2α loss-of-function 
Lee et al58
 
aP2-Cre**
 
wAT, BAT, 
(CNS, PNS36,108,109)
 
15 wks
 
Body weight  
Glucose intolerance and insulin resistance  
AT inflammation 
HIF-1α/2α loss-of-function 
Lee et al58
 
aP2-Cre**
 
wAT, BAT, (CNS, PNS36,108,109)
 
15 wks
 
AT mass  
Glucose intolerance and insulin resistance  
AT inflammation and fibrosis 
Cell line HIF expression Phenotypes
In vitro studies
HIF-1α gain-of-function 
Lin et al77
 
NiH 3T3-L1
 
HiF-1α-ODDΔ
 
Adipogenic differentiation 
HIF-2α gain-of-function 
Shimba et al79
 
NiH 3T3-L1
 
wild type HiF-2α
 
Adipogenic differentiation 
Notes: *Generated by Barbara Kahn group (Beth israel); **generated by Ronald evans Group (Salk institute).
Abbreviations: AT, adipose tissue; BAT, brown adipose tissue; CNS, central nervous system; HFD, high-fat diet; HiF, hypoxia-inducible factor; ODDΔ, oxygen-dependent 
domain deleted; PNS, peripheral nervous system; wAT, white adipose tissue.
(,2%) as compared to lean mice that have oxygen tensions 
ranging from 45 to 55 mmHg.5 Recent studies from our 
group and others have further shown that in obese adipose 
tissues, hypoxia can be detected by the hypoxia-specific 
chemical probe, pimonidazole, as well as by immunohis-
tochemical detection of HIF-1α expression (Figure 2).3,5,22 
In relatively severe hypoxic conditions, pimonidazole 
becomes reduced and binds to sulfhydryl groups of 
various molecules forming pimonidazole adducts in the 
hypoxic cells.63 Although this method is not quantitative 
and it is unable to detect mildly hypoxic tissues (above 
10 mmHg pO2), it has been widely used and shown to be 
effective in consistently detecting tissue hypoxia of cancer 
and ischemia.
Despite compelling evidence of hypoxia in obese adipose 
tissues, the onset mechanisms of adipose tissue hypoxia in 
obesity are not fully understood. Obesity is characterized by 
hyperplasia (cell number increase) as well as hypertrophy Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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(cell size increase) of obese adipocytes resulting in a rapid 
enlargement of adipose tissue. Given that the diffusion 
capacity of oxygen is limited to 150–200 µm, aberrantly 
enlarged adipose tissue may have insufficient intra-adipose 
blood perfusion contributing to hypoxia in these tissues.7 
One can then reason that restoring blood perfusion into 
adipose tissue may attenuate adipose tissue hypoxia and 
adipocyte dysfunction in obesity. Several groups attempted 
to address this by modulating vasculature and VEGF expres-
sion and activity. Rupnick et al have shown that angiogenesis 
inhibitor TNP-470 treatment in ob/ob mice has a profound 
weight-loss effect that is associated with vascular remodel-
ing, decreased endothelial cell proliferation, and increased 
endothelial cell apoptosis without any apparent toxicity in 
3T3-L1 preadipocytes.64 This suggests that weight loss is 
due to an endothelial-mediated antiangiogenic mechanism. 
A subsequent study by Bråkenhielm et al has demonstrated 
that TNP-470 prevents obesity and lowers insulin level sug-
gesting that antiangiogenic therapy may improve insulin 
sensitivity.65 In contrast to these initial observations, a recent 
study by White et al showed that TNP-470 treatment induces 
glucose intolerance indicating that, despite a significant 
weight loss, antiangiogenic vascular suppression may result 
in adipocyte dysfunction and systemic diabetic phenotypes.66 
More direct observations have been reported from studies 
utilizing adipocyte-specific gain-of-function or loss-of-
function VEGF transgenic animals.6 Several studies reported 
that overexpression of VEGF in adipocytes significantly 
attenuated obesity and insulin resistance in high-fat diet-fed 
mice, whereas another study showed that   β-actin-mediated 
partial suppression of systemic VEGF expression displayed 
resistance to   high-fat diet-induced obesity.67–70 One can specu-
late that VEGF derived from non-adipocytes, particularly 
macrophages, may have differential effects on obesity and 
insulin resistance. Although the exact nature of discrepancy 
still remains to be determined, these studies highlight the 
complexity of adipose tissue VEGF and vasculature that 
appear to play a critical role in adipose blood perfusion and 
hypoxia, which in turn, regulate metabolic homeostasis.
In addition to oxygen supply through vasculature, tis-
sue oxygen tension or oxygen availability is determined by 
oxygen consumption rate of local cellular components in 
various physiologic and pathologic conditions.8–10 Our recent 
study provided evidence for the increased oxygen consump-
tion of adipocytes as an initial contributor to adipose tissue 
hypoxia in high-fat diet-induced obesity.58 Intriguingly, 
short-term exposure to a high-fat diet (less than 3 days) was 
sufficient to create adipose tissue hypoxia as determined by 
adipose tissue accumulation of hypoxia probe pimonidazole, 
HIF-1α and its target gene expression, and elevated levels of 
glycolysis and lactate. It should be noted that mice as early 
as 3 days after high-fat diet did not show any significant 
adipose tissue remodeling suggesting that this is independent 
of adipose tissue oxygen perfusion. Although mechanisms 
have not been fully elucidated, saturated free fatty acids 
increase mitochondrial oxygen consumption through the 
adenine nucleotide translocator (ANT)-dependent uncou-
pling of mitochondrial respiration.71,72 ANTs, localized in 
the mitochondrial inner membrane, induce proton leakage by 
pumping protons into the mitochondrial matrix. We showed 
that the oxygen consumption rate of primary adipocytes 
isolated from 3 days high-fat diet-fed mice was significantly 
elevated, even in the presence of oligomycin, indicating the 
uncoupling mechanism. Further, cultured 3T3-L1 adipocytes 
treated with saturated free fatty acids displayed increased 
oxygen consumption, which is inhibited by ANT inhibitor 
carboxyatractyloside. In high-fat diet-fed mice, both phar-
macological (carboxyatractyloside treatment) and genetic 
(viral ANT2 short hairpin RNA knock-down) inhibitions of 
ANT successfully alleviated adipose tissue hypoxia without 
changes in systemic oxygen saturation, which are associated 
with improved glucose tolerance and insulin sensitivity. These 
observations indicate that adipose tissue oxygen consumption 
rate is a critical determinant for adipose tissue hypoxia and 
HIF-1α expression promoting obesity-associated metabolic 
dysfunction.
Taken together, these studies provide evidence for a 
model of adipose tissue hypoxia in obesity. In prolonged or 
chronic obesity, uncontrolled expansion of adipose tissue 
may cause insufficient blood perfusion and oxygen delivery 
leading to perhaps more persistent adipose tissue hypoxia. 
In the short-term or transient manner, prior to adipocyte 
Figure 2 HiF-1α expression in obese adipose tissues.
Notes: (A) Hematoxylin and eosin staining of adipose tissues of obese mice fed a 
high-fat diet for 15 weeks shows enlarged adipocytes with significant inflammatory 
cell infiltration (*). (B) HiF-1α is detected by immunohistochemistry (black arrows) 
in obese adipose tissues.
Abbreviation: HiF, hypoxia-inducible factor.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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hypertrophy and hyperplasia, elevated saturated free fatty 
acids increase adipocyte oxygen consumption resulting in 
a state of relative hypoxia via ANT-mediated uncoupled 
mitochondrial respiration. Although biological significance 
of the relationship between these two distinct mechanisms 
is not fully understood, HIF-mediated hypoxic signaling 
appears to be invariably activated in hypoxic obese adipose 
tissue and exerts a broad and deep influence on adipocyte 
biology and metabolic disorders.
Regulation of adipogenesis  
and adiposity by HIFs
As nutritional intake exceeds energy expenditure, the 
remaining energy is stored in white adipocytes leading to 
  hypertrophy. While hypertrophy prevails and rapidly occurs 
in obesity, the link between hyperplasia and obesity is still 
controversial.73 Considering childhood obesity influences 
adipocyte number in adulthood, it is conceivable that there 
is some kind of positive relevance between excessive food 
intake and hyperplasia.73 One possible mechanism is the 
induction of adipogenesis factors by severe and chronic 
hypertrophy of adipocytes.74 However, the precise mecha-
nism of how obesity affects induction of hyperplasia needs 
to be further studied. In the case of hyperplasia, appropriate 
recruitment of angiogenesis factors needs to be accompanied 
with fat-tissue enlargement.75 During fat-pad expansion, 
adipocytes communicate with endothelial cells via paracrine 
signaling and hypoxia seems to be a critical regulator of 
angiogenesis.75 Given that hypoxia is a prominent feature 
in obese adipose tissues, functional roles of HIFs in adipo-
genic activation and differentiation have been of particular 
interest.
HiF-1α
Early studies have demonstrated that HIFs play an impor-
tant role in in vitro adipogenic differentiation of 3T3-L1 
  preadipocytes (Table 1). He et al reported that HIF-1α 
protein levels were elevated by 3T3-L1 adipocyte differen-
tiation.76 Lin et al showed that hypoxia prevents differen-
tiation of 3T3-L1 by sustaining the expression of pref-1, a 
preadipocyte-secreted inhibitor of adipocyte differentiation.77 
Induction of HIF-1α appears to be a key contributor to the 
hypoxia-mediated maintenance of the undifferentiated state. 
These early in vitro studies suggest that HIFs may play an 
important role in adipogenic differentiation.
Adipocyte-specific ablation of HIF-1α activity in obesity 
animal models provides evidence that HIF-1α may promote 
adipogenesis in high-fat diet-mediated obesity. Adipocyte 
Hif-1α-null mice exhibited less body weight, reduced 
white adipose tissue mass, and reduced adipocyte size on 
high-fat diet.23–25 One study showed that adipocyte-specific 
over  expression of a truncated dominant-negative form of 
HIF-1α resulted in more severe obesity with increased white 
adipose tissue mass.78 However, the biological implication 
of truncated HIF-1α used in this study has not been char-
acterized and obese phenotypes appear to be due to brown 
adipose tissue-dependent mechanisms. Studies conducted 
by Jiang et al and Lee et al demonstrated that adipocyte-
specific deletion of HIF-1β, an obligate partner of HIF-1α, 
results in a lean phenotype and smaller adipocyte size.23,26 
In support of these studies, transgenic overexpression of 
the constitutively active form of HIF-1α (ΔODD-HIF-1α) 
in adipocytes led to increased body weight and adiposity.22 
Our recent study, however, showed that adipocyte Hif-1α-null 
mice exhibit normal body weight on both normal chow and 
high-fat diet.58 Furthermore, there was a significant increase 
in white adipose tissue mass and adipocyte size in adipocyte 
Hif-1α-null mice as compared to wild type control mice. 
Yet, in this study, Hif-1α-null mice exhibited a significant 
improvement in glucose tolerance and insulin sensitivity 
suggesting that adipocyte HIF-1 signaling may exert its 
antidiabetic effects through systemic metabolic regulation 
(eg, fat mobilization or inflammation) rather than regulation 
of adipogenic differentiation.
HiF-2α
In contrast to HIF-1α, HIF-2α overexpression in 3T3-L1 
significantly enhanced the peroxisome proliferator activator 
γ2-mediated adipogenesis that is associated with increased 
glucose uptake and lipid biosynthesis, suggesting that 
HIF-2α promotes in vitro adipogenic differentiation.79 
However, a recent study by Park et al has demonstrated that 
hypoxic induction of Wnt10b suppresses adipogenesis of 
3T3-L1.80 HIF-2α, not HIF-1α, appears to be responsible 
for transactivation of the Wnt10b gene, which maintains 
preadipocytes in an undifferentiated state in hypoxia. We 
recently generated adipocyte-specific HIF-2α knockout 
mice and revealed that HIF-2α ablation in adipocytes aggra-
vates high-fat diet-induced obesity and insulin resistance, 
suggesting that HIF-2α may play a role in suppressing 
adipogenic differentiation and obesity when fed a high-fat 
diet or it may counteract HIF-1α activities as proposed 
previously.58
Despite contradictory observations on functional contribu-
tions of HIFs to adiposity, it illuminates multifaceted roles of 
HIFs in the regulation of adipogenic differentiation in obesity. Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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However, it remains unclear whether aP2, also termed fabp4, 
promoter-driven adipocyte-specific Cre mice used in the 
above-mentioned studies display recombination in preadipo-
cytes.36 Thus, it will be of critical importance to characterize 
HIF signaling in conjunction with the adipocyte cellular 
lineage trace. For example, adipocyte precursor-specific Cre 
lines can be employed to elucidate specific roles of HIFs in 
the differentiation of preadipocytes into adipocytes.81
HIFs and insulin resistance
Association of obstructive sleep apnea that is characterized 
by repetitive cycles of intermittent hypoxia with metabolic 
disorders including obesity and insulin resistance has 
been reported in a number of clinical studies in humans, 
suggesting that oxygen homeostasis is one of the key con-
tributors to glucose metabolism and insulin sensitivity.2,82 
Moreover, lean mice as well as ob/ob mice exposed to 
intermittent hypoxia have been shown to develop systemic 
insulin resistance.83 Regazzetti et al have demonstrated 
that hypoxia is sufficient to suppress the insulin signal-
ing pathway in human and murine adipocytes.84 Hypoxia 
(1% O2) or hypoxia mimetic CoCl2 treatment significantly 
reduced phosphorylation of insulin receptor (IR) and 
protein kinase B in 3T3-L1 and differentiated human 
adipocytes. Moreover, inhibited insulin signaling was 
associated with the reduction of insulin-induced glucose 
uptake. Overexpression of HIF-1α or HIF-2α mimicked 
hypoxia-induced insulin signaling inhibition whereas 
siRNA knockdown of HIF-1α or HIF-2α partially restored 
insulin signaling in hypoxia indicating that HIF signaling 
is an important component of adipocyte insulin signaling. 
Although molecular and cellular mechanisms underly-
ing the links between adipose tissue hypoxia and insulin 
resistance is still poorly understood, recent studies from 
our group and others provide insight into how hypoxic 
adipose microenvironment in high-fat diet-induced obese 
mice affects adipocyte functions. Further, these studies 
provide insight on how adipocyte hypoxic HIF signaling 
influences systemic metabolic homeostasis.
HiF-1α
Adipocyte-specific Hif-1α deletion in high-fat diet-induced 
obese mice consistently exhibits improved glucose toler-
ance and insulin sensitivity. Jiang et al further demonstrated 
that adipocyte Hif-1α-null mice have enhanced systemic 
insulin signaling pathways such as phosphorylation of 
Akt in white adipose tissue, liver, and skeletal muscle.23 
Consistently,   adipocyte Hif-1α-null mice show increased 
expression of adiponectin, which is known to promote energy 
expenditure and insulin sensitivity, and decreased expression 
of SOCS3 that inhibits IR signaling by preventing autophos-
phorylation of IR. Another study by Krishnan et al employed 
aP2 Cre-ERT2 mice allowing the inducible deletion of Hif-1α 
in adipocytes to avoid potential Cre recombination/Hif-1α 
deletion during embryonic and early postnatal development.25 
Upon tamoxifen-induced Hif-1α ablation, high-fat diet-
induced obese mice exhibited a significant improvement in 
systemic metabolism including lean phenotype, increased 
glucose tolerance and insulin sensitivity, and attenuated 
obesity-associated cardiomyopathy. Indirect calorimetric 
analysis revealed that adipocyte loss of HIF-1α promotes 
systemic energy expenditure and fatty acid β-oxidation 
in visceral adipose tissue of high-fat diet-fed mice. The 
authors further showed that peroxisome proliferator-activator 
receptor gamma coactivator-1 alpha (PGC-1α), a central 
transcriptional coactivator of mitochondrial biogenesis and 
energy metabolism, is critically involved in Hif-1α-mediated 
fatty acid oxidation in adipose tissue.85 PGC-1α activity 
is negatively regulated by acetylation at the protein level. 
Intriguingly, PGC-1α was heavily acetylated in the high-fat 
diet-fed wild type mice whereas virtually no acetylation 
was detected in adipocyte Hif-1α-null mice. This suggests 
that loss of HIF-1α results in PGC-1α deacetylation, which 
in turn promotes transcriptional activity of PGC-1α on its 
target genes involved in mitochondrial biogenesis and energy 
expenditure. Accordingly, Hif-1α-null adipocytes contain 
more mitochondria with increased expression of numerous 
PGC-1α target genes. Sirtuin 2, a nicotinamide adenine 
dinucleotide (NAD+)-dependent deacetylase that can target 
PGC-1α,86 was identified to be bound and transcriptionally 
repressed by HIF-1α. Taken together, this study demonstrated 
that HIF-1α/sirtuin 2/PGC-1α axis plays a crucial role in 
regulating fatty acid oxidation and energy expenditure in 
white adipose tissue. In support of the above loss-of-function 
studies, Halberg et al reported that overexpression of a 
constitutively active form of HIF-1α (ΔODD-HIF-1α) in 
adipocytes exhibited increased body weight and decreased 
glucose tolerance, demonstrating that aberrant HIF-1 activity 
leads to an exacerbated diabetic phenotype.22 
Our recent study further provides evidence for the func-
tional contribution of HIF-1α to the hypoxia-associated insu-
lin resistance. Adipocyte Hif-1α deletion improved glucose 
tolerance and systemic insulin sensitivity in muscle, liver, 
and adipose tissue on a high-fat diet.58 At the molecular level, 
we found that HIF-1α-induced iNOS leads to NO produc-
tion in obese adipose tissue. NO has been shown to inhibit Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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insulin signaling by S-nitrosylation-dependent inactivation 
of Akt.87
Adipocyte-specific HIF-1β deletion has also been 
analyzed to evaluate the role of the HIF signaling pathway 
in obesity.23,26 Adipocyte Hif-1β-null mice were lean and 
  resistant to age- and high-fat diet-mediated insulin   resistance. 
These results indicate that mice lacking adipocyte HIF-1β 
exhibit similar phenotypes to HIF-1α knockout mice. How-
ever, it should be noted that the HIF-1β subunit is an obligate 
partner protein for DNA binding and transcription of both 
HIF-1α and HIF-2α, as well as other PAS-domain containing 
proteins such as aryl hydrocarbon receptor.88 Indeed, some 
differential effects of HIF-1α and HIF-1β deletions have 
been indicated. For example, there was a significant differ-
ence in the temporal course of body weight gain and onset 
of improvement of glucose metabolism.23 Nonetheless, these 
studies support the critical roles for hypoxia/HIF signaling 
in adipocytes by regulating metabolic homeostasis.
HiF-2α
Given recently proposed antagonistic roles of HIF-1α and 
HIF-2α in NO homeostasis, HIF-1α promotes NO produc-
tion by inducing its target iNOS, while HIF-2α suppresses 
NO production by inducing its target, arginase, removing 
NO precursor L-arginine.28,33,57 As a result, we sought to 
determine the effects of adipocyte Hif-2α deletion on obe-
sity and glucose metabolism. Adipocyte Hif-2α-null mice 
exhibit increased body weight, reduced glucose tolerance, 
and insulin sensitivity on a high-fat diet that is associated 
with increased NO levels and arginase expression in adi-
pose tissue.58 This suggests that HIF-2α plays a protective 
role against obesity-induced insulin resistance and further 
supports opposing roles of HIF-1α and HIF-2α in adipo-
cyte glucose metabolism. In order to better understand the 
interplay of the two HIF-α isoforms in obesity, we created 
adipocyte-specific HIF-1α/HIF-2α double-knockout mice 
and, intriguingly, found that double-knockout mice appear 
to recapitulate virtually all phenotypes that HIF-1α knock-
out mice exhibit: improved glucose tolerance and insulin 
sensitivity, reduced NO   production, and attenuated adipose 
tissue inflammation and fibrosis. These results suggest that 
HIF-1α exerts predominant roles in contributing to the 
development of obesity-induced insulin resistance, while 
HIF-2α prevents the pathological metabolic progress by 
suppressing HIF-1α activity. Yet, further studies will be 
required to better elucidate the molecular mechanisms 
underlying the opposing interaction between HIF-1α 
and HIF-2α in dysfunctional adipocytes. A possibility of 
HIF-2α having parallel or HIF-1α-independent protective 
mechanisms should not be excluded as well.
HIFs and obesity-associated 
inflammation
One of the hallmarks of obesity is low-grade chronic inflam-
mation in metabolic tissues including adipose tissue.13–15 In 
response to imbalanced metabolic stimuli, adipocytes initiate 
inflammatory signaling pathways that lead to the induction 
of inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α).89–91 Subsequently, various inflammatory cell 
populations are infiltrated into adipose tissues. In particu-
lar, proinflammatory (M1) macrophages have been shown 
to be a prominent immune cell population recruited into 
obese adipose tissues of obese humans as well as genetic or 
dietary-induced obese mice, which further contributes to the 
adipose tissue inflammatory response.15 Although metabolic 
imbalance has been proposed to be a major initial cause of 
the inflammatory response in obesity, molecular and cellular 
processes that regulate inflammatory signaling, cytokine 
expression, and inflammatory cell recruitment remain to be 
elucidated.
HiF-1α
Obesity-associated inflammation contributes to insulin 
resistance and metabolic dysfunction in obesity.13–15 Accord-
ingly, Hif-1α knockout mice exhibiting improved glucose 
tolerance and insulin sensitivity invariably have less inflam-
mation characterized by decreased macrophage infiltration 
and inflammatory cytokine expression as well as reduced 
adipose tissue fibrosis. Kihira et al showed a significant 
decrease in the expression of a macrophage marker, F4/80, 
and crown-like structures resulting from clustered mac-
rophages surrounding dying or dead adipocytes in high-fat 
diet   adipocyte Hif-1α knockout mice.24 Moreover, the 
expression of obesity-associated inflammatory cytokines, 
TNF-α and monocyte chemoattractant protein-1 (MCP-1), 
was decreased in adipose tissues of Hif-1α knockout mice. 
Our recent study also demonstrated a reduction of M1 mac-
rophage infiltration in adipose tissues in the adipocyte Hif-1α 
knockout mice.58 Consistent with these results, macrophage 
markers, such as F4/80 and CD11b, and inflammatory cytok-
ines, such as TNF-α, MCP-1 (CCL2), RANTES (CCL5), 
interleukin-6, macrophage inflammatory protein-1α, and 
CYR62, were significantly reduced in adipose tissues of 
Hif-1α knockout mice. Conditioned medium of Hif-1α-null 
adipocytes showed reduced chemotactic capacity in vitro. 
The diminished chemotaxis of Hif-1α-null adipocytes Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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was confirmed in vivo by   showing decreased migration 
of fluorescently labeled primary macrophages into the 
adipose tissues of Hif-1α knockout mice. Consistently, the 
mice overexpressing a constitutively active form of HIF-1α 
(ΔODD-HIF-1α) in adipocytes showed elevated local adi-
pose tissue   inflammation.22 By gene expression profiling, 
adipose tissue-specific HIF-1α activation led to induction 
of macrophage markers such as F4/80, CD68, and CSF1R, 
as well as monocyte chemoattractants such as CCL2, CCL7, 
and CCL8, along with alteration of extracellular matrix 
(ECM) remodeling genes. Although further follow-up stud-
ies should be warranted to delineate the exact role of HIF-1α, 
the above-noted studies highlight HIF-1α as an essential 
inducer for obesity-associated inflammation.
There is increasing evidence that adipose tissue fibrosis 
and ECM remodeling in obesity may be a key factor that 
induces adipose tissue inflammation and insulin resistance.22,92 
It has been suggested that limiting expansion of adipose tis-
sues by fibrosis may cause adipose tissue dysfunction in 
the obese condition.22,93 An original study by Halberg et al 
demonstrated that adipocyte HIF-1α activation characteristi-
cally induces adipose tissue fibrosis that is associated with 
a general upregulation of a number of ECM molecules and 
their regulators including lysyl oxidase (LOX).22 Consistently, 
genetic or pharmacological inhibition of HIF-1 led to less 
fibrotic accumulation in adipose tissues.93
HiF-2α
Considering opposing roles of HIF-1α and HIF-2α, adi-
pocyte Hif-2α knockout mice exhibited increased adipose 
tissue inflammation on high-fat diet characterized by more 
M1 macrophage infiltration and higher expression of inflam-
matory genes including TNF-α, IL-1, and 5-lipoxygenase-
activating protein.58 This suggests that HIF-2α suppresses 
obesity-associated inflammation in adipose tissues. However, 
it remains to be determined whether HIF-2α contributes 
directly to anti-inflammatory processes or indirectly through 
suppressing proinflammatory activities of HIF-1α.
Targeting hypoxia and HIFs  
for treatment of obesity  
and insulin resistance
For many decades, the focus on treating obesity has been 
nonpharmacological management such as changes in diet 
and degree of physical exercise. Although surgical proce-
dures such as laparoscopic gastric bypass have been effec-
tively used for severely obese patients for over a decade 
without   significant adverse effects, and administration of 
  sympathomimetic drugs has been popular, these treatments 
can be invasive and dangerous to the patients.94,95 Recently, 
there has been an effort to reduce and reverse the hyperplasia 
in adipose tissue by inhibiting angiogenesis based on the 
hypothesis that the hyperplasia of white adipose tissue is 
dependent on angiogenesis.96–98 Angiostatin and endostatin, 
the endogenous inhibitors that act via inhibition of Col1 
expression and c-Jun N-terminal kinase (JNK) pathway, were 
shown to reduce the body weight of obese mice. TNP-470 
and VEGFR2-specific inhibitors have also been shown to 
prevent obesity in ob/ob mice subjected to a high-fat diet.65,66 
TNP-470 is an antibiotic, which has antineoplastic effect in 
mammalian tissues. Its mechanism has been proposed to be 
an inactivation of methionine aminopeptidase 2 and an induc-
tion of p53 pathway.99 Alongside the normalization of white 
adipose tissue, TNP-470 also alleviates insulin insensitivity. 
However, it has also been shown to be neurotoxic which may 
alter appetite in test subjects and requires further investiga-
tion. Other potential therapeutic agents, such as a specific 
peptide motif that binds a specific vascular marker in white 
adipose tissue, were shown to have a positive effect but do 
not induce apoptosis. Given that antiangiogenic approaches 
may promote hypoxia and HIF-1 activity, further investiga-
tion will be required to evaluate the therapeutic potential of 
antiangiogenesis.
Given profound contributions of hypoxia to the devel-
opment of obesity and insulin resistance as well as a 
significant attenuation of obesity and/or insulin resistance 
phenotypes in mice lacking HIF-1α in adipose tissue, one 
can argue for HIF-1 inhibition as a potential therapeutic 
strategy for obesity and insulin resistance. Two of these 
therapeutic agents, PX-478 and digoxin, have been recently 
tested on high-fat diet-induced obesity animal model by 
Sun et al.93 PX-478 (S-2-  amino-3-[4’-N,N,-bis(chloroethyl)
amino]phenyl propionic acid N-oxide dihydrochloride) 
is a potent HIF-1α inhibitor that was initially identified 
via high-throughput screening for compounds that inhibit 
HIF-1α expression and tumor growth.100 Although its 
mechanisms of inhibiting HIF-1α protein accumulation are 
not fully understood, recent studies suggest that PX-478 
may inhibit HIF-1α via multiple mechanisms including 
transcription, translation, and protein degradation.101 
HIF-1α inhibition by systemic PX-478 administration 
normalized high-fat diet-induced body weight gain and 
fat mass, indicating that overall adiposity was reduced. 
The fasting glucose levels and insulin sensitivity were also 
improved and energy expenditure was increased by PX-478 
administration. Aberrant plasma levels of   cholesterol, Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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triglycerides, and leptin, as well as local adipose tissue 
leptin expression, were normalized in PX-478-treated 
mice. Furthermore, PX-478 treatment led to the reduction 
of inflammatory cytokines and adipose tissue macrophage 
infiltration. This is associated with decreased expression 
of fibrotic genes including Col1, Col3, and lysyl oxidase 
as well as reduced ECM accumulation.
A cardiac glycoside, digoxin, was identified through 
a library screening for a potential small-molecule HIF-1 
inhibitor.102 The administration of digoxin and other 
cardiac glycosides showed a significant anticancer effect 
by inhibiting HIF-1α translation. Digoxin also showed 
potent beneficial anti-obese and antidiabetic effects in 
high-fat diet mice.93 Digoxin may have molecular targets 
other than HIF-1 and has a relatively narrow therapeutic 
index. Despite this limitation, digoxin has been a com-
monly prescribed drug for the treatment of heart failure. 
If the efficacy on obesity and insulin resistance could be 
guaranteed, further studies for safe use of this drug should 
be considered.
Taken together, these studies provide a   proof-of-concept 
for HIF-1α inhibition as a novel therapeutic strategy to 
modify the detrimental obesity-induced tissue inflamma-
tion and insulin resistance. Intriguingly, a recent study by 
Rahtu-Korpela et al has shown that prolyl 4-hydroxylase-2 
(P4H-2) inhibition, which stabilizes HIFs, protected 
against obesity and insulin resistance, indicating that acti-
vation of HIF could be used as a therapeutic strategy for 
Obesity 
Excessive energy intake
Lack of physical activity
Elevated oxygen consumption
Uncoupled mitochondrial respiration
Inadequate blood perfusion
Adipocyte hyperplasia and hypertrophy
Hypoxia
HIF-1α HIF-2α
PX‐478
Digoxin
Adipogenesis
Preadipocyte
proliferation and differentiation Inflammation Fibrosis
Glucose intolerance
Insulin resistance
Metabolic disorders
?
?
?
Figure 3 Regulation of obesity and diabetes by HiFs.
Notes: In obesity, insufficient blood perfusion and elevated oxygen consumption result in adipose tissues hypoxia that leads to induction of HIFs. HIF-1α contributes to the 
development of insulin resistance and other metabolic disorders by promoting obesity-associated inflammation and fibrosis. In contrast, HIF-2α exhibits protective roles against 
HiF-1α-mediated diabetic phenotypes. The pharmacological modulation of HiF activities can be an effective therapeutic strategy for antiobesity and diabetes therapies.
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  obesity and associated phenotypes.103 Although, this study 
utilized whole-body p4h2-deficient mice and pharmaco-
logical administration of P4H inhibitor which may exert 
antiobesity and antidiabetic effects through modulating 
nonadipose tissues such as liver and muscle and/or through 
HIF-independent mechanisms. This accentuates the poten-
tial adverse outcomes in targeting HIF-1α in obesity and 
metabolic dysfunction.
Conclusion
Despite that a number of preclinical and clinical studies have 
repeatedly demonstrated the causal association of adipose tis-
sue inflammation with insulin resistance, molecular cues that 
link between obesity, inflammation, and insulin resistance 
still remain to be delineated. Recent advancements identify-
ing hypoxia as a prominent microenvironmental component 
of obese adipose tissue directs us toward the missing link 
(Figure 3): HIF-1 signaling that leads to the development 
of obesity-associated inflammation and insulin resistance. 
A number of small-molecule compounds and antisense 
oligonucleotides that inhibit HIF-1 activity in novel ways 
are currently in development or clinical trial.104–106 Thus, 
it is imperative that we gain a better understanding of how 
HIF-1 signaling exerts adipose tissue inflammation and 
insulin resistance.
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